BCM
ENZ

Bridgeway Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Bridgeway Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,200
Closed -$28.6K – 1283
2025
Q1 		$28.6K Sell
77,200
-100,000
-56% -$55.3K ﹤0.01% 1147
2024
Q4 		$127K Sell
177,200
-3,600
-2% -$3.73K ﹤0.01% 1083
2024
Q3 		$202K Buy
180,800
+48,700
+37% +$54.5K ﹤0.01% 1062
2024
Q2 		$144K Sell
132,100
-95,000
-42% -$107K ﹤0.01% 1118
2024
Q1 		$288K Hold
227,100
– – 0.01% 1045
2023
Q4 		$316K Hold
227,100
– – 0.01% 1056
2023
Q3 		$318K Sell
227,100
-82,299
-27% -$124K 0.01% 1001
2023
Q2 		$569K Sell
309,399
-6,101
-2% -$14.1K 0.01% 870
2023
Q1 		$767K Sell
315,500
-5,200
-2% -$7.73K 0.02% 787
2022
Q4 		$459K Hold
320,700
– – 0.01% 905
2022
Q3 		$715K Sell
320,700
-55,000
-15% -$133K 0.02% 805
2022
Q2 		$778K Buy
375,700
+300
+0.1% +$742 0.02% 785
2022
Q1 		$1.09M Buy
375,400
+64,200
+21% +$206K 0.02% 761
2021
Q4 		$999K Buy
311,200
+35,000
+13% +$119K 0.02% 790
2021
Q3 		$978K Buy
276,200
+55,000
+25% +$183K 0.02% 839
2021
Q2 		$701K Sell
221,200
-37,500
-14% -$118K 0.01% 973
2021
Q1 		$890K Sell
258,700
-60,700
-19% -$189K 0.02% 904
2020
Q4 		$805K Sell
319,400
-98,600
-24% -$215K 0.02% 793
2020
Q3 		$882K Buy
418,000
+163,100
+64% +$388K 0.02% 719
2020
Q2 		$571K Sell
254,900
-120,600
-32% -$310K 0.01% 815
2020
Q1 		$950K Sell
375,500
-50,600
-12% -$124K 0.02% 570
2019
Q4 		$1.12M Hold
426,100
– – 0.02% 709
2019
Q3 		$1.53M Sell
426,100
-1,300
-0.3% -$4.6K 0.02% 608
2019
Q2 		$1.44M Sell
427,400
-4,200
-1% -$14.8K 0.02% 638
2019
Q1 		$1.18M Buy
431,600
+266,000
+161% +$871K 0.01% 700
2018
Q4 		$460K Hold
165,600
– – 0.01% 1022
2018
Q3 		$682K Buy
165,600
+40,600
+32% +$184K 0.01% 1050
2018
Q2 		$649K Buy
+125,000
New +$762K 0.01% 1049
2017
Q2 		– Sell
-232,700
Closed -$1.95M – 1480
2017
Q1 		$1.95M Sell
232,700
-90,000
-28% -$634K 0.02% 585
2016
Q4 		$2.24M Buy
322,700
+39,500
+14% +$252K 0.03% 543
2016
Q3 		$1.44M Sell
283,200
-25,000
-8% -$149K 0.02% 655
2016
Q2 		$1.84M Hold
308,200
– – 0.03% 558
2016
Q1 		$1.4M Buy
308,200
+500
+0.2% +$2.23K 0.02% 632
2015
Q4 		$1.39M Hold
307,700
– – 0.03% 616
2015
Q3 		$975K Buy
307,700
+33,000
+12% +$100K 0.02% 760
2015
Q2 		$832K Buy
274,700
+34,500
+14% +$97K 0.02% 864
2015
Q1 		$709K Sell
240,200
-500
-0.2% -$1.64K 0.01% 940
2014
Q4 		$1.07M Sell
240,700
-150
-0.1% -$715 0.02% 746
2014
Q3 		$1.24M Hold
240,850
– – 0.03% 671
2014
Q2 		$1.26M Buy
240,850
+650
+0.3% +$2.81K 0.03% 681
2014
Q1 		$999K Hold
240,200
– – 0.03% 749
2013
Q4 		$701K Hold
240,200
– – 0.02% 886
2013
Q3 		$605K Hold
240,200
– – 0.02% 938
2013
Q2 		$500K Buy
+240,200
New +$530K 0.02% 938

Other funds holding ENZ

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

Bridgeway Capital Management's ENZ Position: Q2 2025 in Review

Bridgeway Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 77,200 shares — an estimated $28.6K sold.

Bridgeway Capital Management first reported a position in ENZ in Q2 2013 and held it in 44 quarters. The position peaked at $2.24M in Q4 2016. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • Bridgeway Capital Management reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 77,200 Enzo Biochem, Inc. shares in Q2 2025, an estimated $28.6K.
  • Bridgeway Capital Management first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 44 quarters.
  • Bridgeway Capital Management's Enzo Biochem, Inc. position peaked at $2.24M in Q4 2016.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.